CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below.
All CIRM Grants
Search Filters »
| Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
| University of California, Los Angeles |
Dr. Scott G Kitchen |
Therapeutic Translational Research Projects |
Hematopoietic Stem/Progenitor Cell-Based Chimeric Antigen Receptor Gene Therapy for HIV Infection |
$6,140,723 |
| Rejuvenation Technologies, Inc. |
John Ramunas |
Therapeutic Translational Research Projects |
Telomerase mRNA for short telomere related pulmonary fibrosis |
$3,984,942 |
| University of Southern California |
Dr. Rongfu Wang |
Therapeutic Translational Research Projects |
Novel T cell receptor-STEM T cell immunotherapy in lung cancer |
$5,689,540 |
| Stanford University |
Walter Park |
Therapeutic Translational Research Projects |
Enhanced Autologous Pancreatic Islet Transplantation and Survival for Diabetes Mellitus Therapy |
$6,054,165 |
| VxBiosciences inc. |
Dr. Christina Chuong |
Therapeutic Translational Research Projects |
Escape-Resistant Oligonucleotide Therapy (ONT) for Cytomegalovirus (CMV) Disease in Hematopoietic Stem-Cell and Solid-Organ Transplant Patients |
$3,977,180 |
| City of Hope, Beckman Research Institute |
Dr Jianhua Yu |
Therapeutic Translational Research Projects |
Specific Targeting Hypoxia Metastatic Breast Tumor with Allogeneic Off-the-Shelf Anti-EGFR CAR NK Cells Expressing an ODD domain of HIF-1α |
$6,036,002 |
| Mahzi Therapeutics |
Dr. Allyson Berent |
Therapeutic Translational Research Projects |
Development of a Gene Therapy for the Treatment of Pitt Hopkins Syndrome (PHS) – Translating from Animal Proof of Concept to Support Pre-IND Meeting |
$3,800,760 |
| University of California, Davis |
Dr. William J Murphy |
Therapeutic Translational Research Projects |
Overcoming resistance to standard CD19-targeted CAR T using a novel triple antigen targeted vector |
$3,869,061 |
| University of California, San Diego |
Stephanie Cherqui |
Therapeutic Translational Research Projects |
CRISPR/Cas9-mediated gene editing of Hematopoietic stem and progenitor cells for Friedreich’s ataxia |
$4,846,579 |
| University of Southern California |
Preet M Chaudhary |
Therapeutic Translational Research Projects |
Next generation affinity-tuned CAR for prostate cancer |
$5,805,144 |
| University of California, Los Angeles |
Dr. Donald B. Kohn PhD |
Therapeutic Translational Research Projects |
Autologous MPO Knock-Out Hematopoietic Stem and Progenitor Cells for Pulmonary Arterial Hypertension |
$4,751,297 |
| Ray Therapeutics, INC |
Paul Bresge |
Therapeutic Translational Research Projects |
Optogenetic therapy for treating retinitis pigmentosa and other inherited retinal diseases |
$3,999,553 |
| University of California, Irvine |
Dr. Aileen J Anderson |
Therapeutic Translational Research Projects |
A human neural stem cell therapeutic candidate for the treatment of chronic cervical spinal cord injury |
$4,950,024 |
| University of California, San Francisco |
Arun P Wiita |
Therapeutic Translational Research Projects |
CD72 nanoCARs for the treatment of refractory pediatric B-cell acute lymphoblastic leukemia |
$3,330,801 |
| MyoGene Bio LLC |
Dr Courtney Young |
Therapeutic Translational Research Projects |
Development of MyoDys45-55, a gene editing therapy for Duchenne muscular dystrophy |
$3,400,000 |
| Immusoft Corporation |
Dr Robert Hayes |
Therapeutic Translational Research Projects |
MPS II: Plasma cell delivery of iduronate sulfatase |
$3,994,676 |
| Regencor, Inc. |
PILAR RUIZ-LOZANO |
Therapeutic Translational Research Projects |
IND-enabling Studies of Wearable Evolve-FSTL1 for Cardiac Regeneration after MI |
$3,923,191 |
| University of California, San Francisco |
Dr. Hideho Okada |
Therapeutic Translational Research Projects |
Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma |
$4,556,536 |
| ImmunoVec |
Luke Riggan |
Therapeutic Translational Research Projects |
Hematopoietic Stem Cell Gene Therapy for IPEX Syndrome |
$3,551,332 |
| University of California, Los Angeles |
Dr. Arjun Deb |
Therapeutic Translational Research Projects |
Targeting stromal progenitors to prevent the development of heart failure |
$4,714,824 |
| Palo Alto Veterans Institute for Research |
Irene Lorenzo Llorente |
Therapeutic Translational Research Projects |
Clinical Translation of Allogenic Regenerative Cell Therapy for White Matter Stroke and Vascular Dementia |
$5,149,913 |
| University of California, Los Angeles |
Dr. Irene L. Llorente |
Therapeutic Translational Research Projects |
Clinical Translation of Allogenic Regenerative Cell Therapy for White Matter Stroke and Vascular Dementia |
$707,754 |
| Juvena Therapeutics Inc. |
Jeremy D O’Connell |
Therapeutic Translational Research Projects |
Clinical Translation of hESC-derived protein therapy that positively regulates the regenerative capacity of post-natal muscle for treating DM1 |
$3,906,376 |
| University of California, Los Angeles |
Cristina Puig Saus |
Therapeutic Translational Research Projects |
CAR-Tnm cell therapy for melanoma targeting TYRP-1 |
$5,904,462 |
| University of California, Los Angeles |
Dr. Lili Yang |
Therapeutic Translational Research Projects |
HSC-Engineered Off-The-Shelf CAR-iNKT Cell Therapy for Multiple Myeloma |
$5,281,199 |
| University of California, San Francisco |
Dr. Hideho Okada |
Therapeutic Translational Research Projects |
Development of novel synNotch CART cell therapy in patients with recurrent EGFRvIII+ glioblastoma |
$525,000 |
| Sanford Burnham Prebys Medical Discovery Institute |
Dr. Evan Y. Snyder |
Therapeutic Translational Research Projects |
Human Neural Stem Cells (hNSCs) for neuroprotection in perinatal hypoxic-ischemic brain injury (HII)-Pre-IND-enabling Studies |
$4,963,684 |
| Neurona Therapeutics |
Dr. Cory R Nicholas |
Therapeutic Translational Research Projects |
Development of a human stem cell-derived inhibitory neuron therapeutic for the treatment of chronic focal epilepsy |
$4,848,505 |
| University of California, San Diego |
Mark H Tuszynski |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Neural Stem Cells for Severe Spinal Cord Injury (SCI) |
$6,235,897 |
| University of California, Los Angeles |
Yvonne Y. Chen |
Therapeutic Translational Research Projects |
BCMA/CS1 Bispecific CAR-T Cell Therapy to Prevent Antigen Escape in Multiple Myeloma |
$3,176,805 |
| University of California, Irvine |
Dr. Brian J. Cummings |
Therapeutic Translational Research Projects |
An optimized human neural stem cell line (hNSC) for the treatment of traumatic brain injury (TBI) |
$4,804,737 |
| City of Hope, Beckman Research Institute |
Prof. Karen S Aboody M.D. |
Therapeutic Translational Research Projects |
Neural Stem cell-mediated oncolytic immunotherapy for ovarian cancer |
$2,873,262 |
| University of California, Los Angeles |
Dr. Caroline Y. Kuo |
Therapeutic Translational Research Projects |
Ex Vivo Gene Editing of Human Hematopoietic Stem Cells for the Treatment of X-Linked Hyper-IgM Syndrome |
$4,896,628 |
| University of Southern California |
Dr. Mark S Humayun |
Therapeutic Translational Research Projects |
PRPE-SF, polarized hESC-derived RPE Soluble Factors, as a Therapy for Early Stage Dry Age-related Macular Degeneration |
$3,697,935 |
| Stanford University |
Dr. Theodore Leng |
Therapeutic Translational Research Projects |
NeuBright, a purified allogeneic cell therapy product for treatment of Dry Age-related Macular Degeneration |
$4,235,758 |
| University of California, Los Angeles |
Steven Schwartz |
Therapeutic Translational Research Projects |
Clinical Translation of Autologous Regenerative Cell Therapy for Blindness |
$5,068,026 |
| University of California, San Francisco |
Dr. Karin Lindgren Gaensler |
Therapeutic Translational Research Projects |
Developing engineered autologous leukemia vaccines to target residual leukemic stem cells |
$4,171,728 |
| University of California, Irvine |
Dr. Magdalene J Seiler |
Therapeutic Translational Research Projects |
Morphological and functional integration of stem cell derived retina organoid sheets into degenerating retina models |
$4,769,039 |
| Stanford University |
Dr. Bertha Chen |
Therapeutic Translational Research Projects |
Autologous iPSC-derived smooth muscle cell therapy for treatment of urinary incontinence |
$5,977,155 |
| MAX BioPharma, Inc. |
Dr. Farhad Parhami Phd, MBA |
Therapeutic Translational Research Projects |
Therapeutic development of Oxy200, an oxysterol with bone anabolic and anti-resorptive properties for intervention in osteoporosis |
$1,400,000 |
| University of California, San Diego |
Dan S Kaufman |
Therapeutic Translational Research Projects |
Human Embryonic Stem Cell-Derived Natural Killer Cells for Cancer Treatment |
$3,260,000 |
| University of California, San Diego |
Catriona Jamieson |
Therapeutic Translational Research Projects |
A Splicing Modulator Targeting Cancer Stem Cells in Acute Myeloid Leukemia |
$2,511,767 |
| Stanford University |
Dr. Anthony E. Oro |
Therapeutic Translational Research Projects |
DEBCT: Genetically Corrected, Induced Pluripotent Cell-Derived Epithelial Sheets for Definitive Treatment of Dystrophic Epidermolysis Bullosa |
$5,107,353 |
| University of California, San Diego |
Ezra Cohen |
Therapeutic Translational Research Projects |
Development of ROR1 CAR-T cells to target cancer stem cells in advanced malignancies |
$5,795,584 |
| University of California, San Diego |
Dr Karen Christman |
Therapeutic Translational Research Projects |
Injectable pro-regenerative scaffold for treating symptomatic peripheral artery disease |
$2,839,317 |
| Gladstone Institutes, J. David |
Dr. Yadong Huang |
Therapeutic Translational Research Projects |
Human iPSC-derived GABAergic Progenitors for Alzheimer’s Disease Treatment |
$1,900,000 |
| University of California, San Francisco |
Mark C. Walters M.D. |
Therapeutic Translational Research Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$60,635 |
| UCSF Benioff Children’s Hospital Oakland |
Dr. Mark C. Walters M.D. |
Therapeutic Translational Research Projects |
Curing Sickle cell Disease with CRISPR-Cas9 genome editing |
$4,394,276 |
| University of Southern California |
Dr. Denis A Evseenko Dr. |
Therapeutic Translational Research Projects |
Pluripotent stem cell-derived chondrocytes for articular cartilage repair |
$2,503,104 |
| Ankasa Regenerative Therapeutics, Inc. |
Ying Zhu |
Therapeutic Translational Research Projects |
An autologous somatic stem cell therapy for the treatment of osteonecrosis |
$2,088,780 |
